Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - Taysha Gene Therapies, Inc. reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.08, representing an earnings surprise of -12.50% [1] - The company posted revenues of $1.79 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 4.54$4.75 million in the same quarter last year [2] - Over the last four quarters, Taysha Gene Therapies has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] Stock Performance - Taysha Gene Therapies shares have increased approximately 35% since the beginning of the year, outperforming the S&P 500's gain of 25.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of$1.88 million, and for the current fiscal year, it is -$0.35 on revenues of$8.27 million [7] Industry Outlook - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]